Profound Medical Corp Stock News

TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, announced today that management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026 in New York City.

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the appointment of Richard Fabian as its new President, effective immediately.

Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day

TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the promotion of Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately. Mr. Sobczyk, who first joi...

A patient-centered initiative focused on education, connection, and support A patient-centered initiative focused on education, connection, and support

– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, commercial and reimbursement momentum continues – – Company reiterates full-year 2026 revenue guidance – – Announces first employer owned health plans to list the TULSA Procedure™ as a covered s...

– Whole-gland TULSA ablation demonstrates statistically significant superior penile length preservation compared to robotic RP at 1 month – – Whole-gland TULSA ablation demonstrates statistically significant superior penile length preservation compared to robotic RP at 1 month –